CO5540385A2 - Derivados quirales de acido oxazol arilpropionico, su metodo de sintesis ycomposiciones farmaceuticas que los contienen - Google Patents
Derivados quirales de acido oxazol arilpropionico, su metodo de sintesis ycomposiciones farmaceuticas que los contienenInfo
- Publication number
- CO5540385A2 CO5540385A2 CO05029209A CO05029209A CO5540385A2 CO 5540385 A2 CO5540385 A2 CO 5540385A2 CO 05029209 A CO05029209 A CO 05029209A CO 05029209 A CO05029209 A CO 05029209A CO 5540385 A2 CO5540385 A2 CO 5540385A2
- Authority
- CO
- Colombia
- Prior art keywords
- fluoro
- alkoxy
- arilpropionic
- oxazol
- pharmaceutical compositions
- Prior art date
Links
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 title 1
- 239000002253 acid Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000001308 synthesis method Methods 0.000 title 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 7
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 125000006239 protecting group Chemical group 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003302 alkenyloxy group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 230000008030 elimination Effects 0.000 abstract 1
- 238000003379 elimination reaction Methods 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000004428 fluoroalkoxy group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
1.- Compuestos de fórmula (I)En dondeR1 es arilo o heteroarilo;R2 es hidrógeno, alquilo inferior, o fluoro-alquilo inferior;R3 y R4 independientemente uno del otro son hidrógeno,hidroxi, halógeno, alquilo inferior, fluoro-alquilo inferior, hidroxi-alquilo inferior, alcoxi inferior-alquilo inferior, alcoxi inferior, fluoro-alcoxi inferior, hidroxi-alcoxi inferior, alcoxi inferior-alcoxi-inferior, o alquenilo inferior,en donde al menos uno de R3 y R4 no es hidrógeno;R5 es alcoxi inferior, fluoro-alcoxi inferior, alqueniloxi inferior, fluoro-alqueniloxi inferior, ariloxi, aril-alcoxi inferior, o aril-fluoro-alcoxi inferior;R6 es hidrógeno o alquilo inferior;n es 1;y sales aceptables farmacéuticamente y/o ésteres aceptables farmacéuticamente de los mismos17.- Un proceso para la elaboración de compuestos de acuerdo con cualquiera de las reivindicaciones 1 a 16, cuyo proceso comprende la elimincación de un grupo protector en un compuesto de formula ( I I )en donde R1, R2, R3, R4, R5 y n son tal como se definen en cualquiera de las reivindicaciones 1 a 17 y PG es un grupo protector.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02022286 | 2002-10-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5540385A2 true CO5540385A2 (es) | 2005-07-29 |
Family
ID=32049977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO05029209A CO5540385A2 (es) | 2002-10-07 | 2005-04-04 | Derivados quirales de acido oxazol arilpropionico, su metodo de sintesis ycomposiciones farmaceuticas que los contienen |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US6969725B2 (es) |
| EP (1) | EP1551814B1 (es) |
| JP (1) | JP4414886B2 (es) |
| KR (1) | KR100623819B1 (es) |
| CN (1) | CN100415727C (es) |
| AR (1) | AR041481A1 (es) |
| AT (1) | ATE402153T1 (es) |
| AU (1) | AU2003273949B2 (es) |
| BR (1) | BR0315114A (es) |
| CA (1) | CA2499721C (es) |
| CO (1) | CO5540385A2 (es) |
| DE (1) | DE60322408D1 (es) |
| DK (1) | DK1551814T3 (es) |
| ES (1) | ES2311110T3 (es) |
| GT (1) | GT200300218A (es) |
| HR (1) | HRP20050308A2 (es) |
| IL (1) | IL167250A (es) |
| MX (1) | MXPA05003392A (es) |
| MY (1) | MY143576A (es) |
| NO (1) | NO330171B1 (es) |
| NZ (1) | NZ538465A (es) |
| PA (1) | PA8584501A1 (es) |
| PE (1) | PE20040591A1 (es) |
| PL (1) | PL208743B1 (es) |
| PT (1) | PT1551814E (es) |
| RU (1) | RU2303593C2 (es) |
| SI (1) | SI1551814T1 (es) |
| TW (1) | TWI343915B (es) |
| UY (1) | UY28006A1 (es) |
| WO (1) | WO2004031162A1 (es) |
| ZA (1) | ZA200502664B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7105551B2 (en) * | 2000-12-20 | 2006-09-12 | Smithkline Beecham Corporation | Thiazole derivatives for treating PPAR related disorders |
| TWI343915B (en) * | 2002-10-07 | 2011-06-21 | Hoffmann La Roche | Chirale ppar agonists |
| AU2003302111A1 (en) * | 2002-11-15 | 2004-06-15 | Cadila Healthcare Limited | Substituted aralkyl derivatives |
| US7262303B2 (en) * | 2003-09-29 | 2007-08-28 | Hoffman-La Roche Inc. | Process for the production of chiral propionic acid derivatives |
| GB2460784A (en) * | 2007-03-07 | 2009-12-16 | Dong A Pharmtech Co Ltd | Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators,method of the same,and pharmaceutical composition |
| RU2361581C2 (ru) | 2007-09-14 | 2009-07-20 | Закрытое Акционерное Общество "Мастерклон" | Фармацевтическая композиция, обладающая противодиабетической, гиполипидемической, гипогликемической и гипохолестеринемической активностью, способ ее получения и способы лечения указанных заболеваний |
| WO2010048207A2 (en) * | 2008-10-21 | 2010-04-29 | Metabolex, Inc. | Aryl gpr120 receptor agonists and uses thereof |
| AR074760A1 (es) | 2008-12-18 | 2011-02-09 | Metabolex Inc | Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico. |
| CN101805337B (zh) * | 2009-02-13 | 2012-05-23 | 天津药物研究院 | 一类含脯氨酸和异恶唑骨架的化合物、其制备方法和用途 |
| CN101805336B (zh) * | 2009-02-13 | 2012-05-30 | 天津药物研究院 | 一类含色氨酸和异恶唑骨架的化合物、其制备方法和用途 |
| US8637096B2 (en) | 2009-12-04 | 2014-01-28 | Curtis C. Stojan | Compositions and method for enhancing insulin activity |
| US8299117B2 (en) | 2010-06-16 | 2012-10-30 | Metabolex Inc. | GPR120 receptor agonists and uses thereof |
| CN102285933B (zh) | 2010-06-18 | 2016-03-09 | 浙江海正药业股份有限公司 | 一种对亚型过氧化物酶增殖物激活受体具有激动作用的化合物、其制备方法和应用 |
| EP2758041B1 (de) | 2011-09-20 | 2021-01-13 | Basf Se | Niedermolekulare modulatoren des kälte-menthol-rezeptors trpm8 und deren verwendung |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5089514A (en) * | 1990-06-14 | 1992-02-18 | Pfizer Inc. | 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents |
| GB9604242D0 (en) * | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
| SK21099A3 (en) * | 1996-08-19 | 2000-05-16 | Japan Tobacco Inc | Propionic acid derivatives and applications thereof |
| DE69914557T2 (de) * | 1998-03-30 | 2005-01-05 | Japan Tobacco Inc. | Verfahren zur herstellung einer isooxazolidindion-verbindung |
| MY123337A (en) * | 1998-05-11 | 2006-05-31 | Takeda Chemical Industries Ltd | Oxyiminoalkanoic acid derivatives. |
| GB9817118D0 (en) * | 1998-08-07 | 1998-10-07 | Glaxo Group Ltd | Pharmaceutical compounds |
| RU2219172C2 (ru) * | 1999-04-06 | 2003-12-20 | Санкио Компани, Лимитед | α-ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ КАРБОНОВЫХ КИСЛОТ |
| TW200514783A (en) | 1999-09-22 | 2005-05-01 | Bristol Myers Squibb Co | Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method |
| DE10031657A1 (de) | 2000-06-29 | 2002-01-24 | Siemens Ag | Hochfrequenz-Bauelement |
| EA200300286A1 (ru) * | 2000-08-23 | 2003-08-28 | Эли Лилли Энд Компани | Агонисты активируемых пероксисомальным пролифератором рецепторов |
| PL208074B1 (pl) * | 2001-05-15 | 2011-03-31 | Hoffmann La Roche | Pochodne oksazolu, sposób ich wytwarzania, środek farmaceutyczny i zastosowanie pochodnych oksazolu |
| TWI343915B (en) * | 2002-10-07 | 2011-06-21 | Hoffmann La Roche | Chirale ppar agonists |
-
2003
- 2003-10-03 TW TW092127469A patent/TWI343915B/zh not_active IP Right Cessation
- 2003-10-03 AR ARP030103607A patent/AR041481A1/es active IP Right Grant
- 2003-10-06 DK DK03757914T patent/DK1551814T3/da active
- 2003-10-06 KR KR1020057005924A patent/KR100623819B1/ko not_active Expired - Fee Related
- 2003-10-06 US US10/679,604 patent/US6969725B2/en not_active Expired - Fee Related
- 2003-10-06 AT AT03757914T patent/ATE402153T1/de active
- 2003-10-06 DE DE60322408T patent/DE60322408D1/de not_active Expired - Lifetime
- 2003-10-06 GT GT200300218A patent/GT200300218A/es unknown
- 2003-10-06 AU AU2003273949A patent/AU2003273949B2/en not_active Ceased
- 2003-10-06 PA PA20038584501A patent/PA8584501A1/es unknown
- 2003-10-06 SI SI200331311T patent/SI1551814T1/sl unknown
- 2003-10-06 EP EP03757914A patent/EP1551814B1/en not_active Expired - Lifetime
- 2003-10-06 WO PCT/EP2003/011030 patent/WO2004031162A1/en not_active Ceased
- 2003-10-06 MX MXPA05003392A patent/MXPA05003392A/es active IP Right Grant
- 2003-10-06 CN CNB2003801010744A patent/CN100415727C/zh not_active Expired - Fee Related
- 2003-10-06 ES ES03757914T patent/ES2311110T3/es not_active Expired - Lifetime
- 2003-10-06 CA CA2499721A patent/CA2499721C/en not_active Expired - Fee Related
- 2003-10-06 RU RU2005114373/04A patent/RU2303593C2/ru not_active IP Right Cessation
- 2003-10-06 NZ NZ538465A patent/NZ538465A/en not_active IP Right Cessation
- 2003-10-06 HR HR20050308A patent/HRP20050308A2/xx not_active Application Discontinuation
- 2003-10-06 UY UY28006A patent/UY28006A1/es not_active Application Discontinuation
- 2003-10-06 BR BR0315114-0A patent/BR0315114A/pt active Search and Examination
- 2003-10-06 PT PT03757914T patent/PT1551814E/pt unknown
- 2003-10-06 PE PE2003001007A patent/PE20040591A1/es not_active Application Discontinuation
- 2003-10-06 JP JP2004540787A patent/JP4414886B2/ja not_active Expired - Fee Related
- 2003-10-06 PL PL376363A patent/PL208743B1/pl not_active IP Right Cessation
- 2003-10-06 MY MYPI20033798A patent/MY143576A/en unknown
-
2005
- 2005-02-24 NO NO20051011A patent/NO330171B1/no not_active IP Right Cessation
- 2005-03-03 IL IL167250A patent/IL167250A/en not_active IP Right Cessation
- 2005-04-01 ZA ZA200502664A patent/ZA200502664B/en unknown
- 2005-04-04 CO CO05029209A patent/CO5540385A2/es not_active Application Discontinuation
- 2005-07-18 US US11/183,360 patent/US7348349B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5540385A2 (es) | Derivados quirales de acido oxazol arilpropionico, su metodo de sintesis ycomposiciones farmaceuticas que los contienen | |
| AR035892A1 (es) | Derivados de oxazol, proceso para su preparacion, composiciones farmaceuticas que los comprenden, y el uso de dichos compuestos en la preparacion de medicamentos | |
| AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
| CU23413B7 (es) | Nuevos derivados de benzoimidazol útiles como agentes antiproliferativos | |
| ES2221440T3 (es) | Derivados de acido aminofenoxiacetico como neuroprotectores. | |
| AR023152A1 (es) | Compuesto tienopirimidina, procedimiento para producirlo, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar dichacomposicion | |
| AR029301A1 (es) | Compuestos derivados de biarilo, metodos para su preparacion composiciones que los contienen, su uso como agonistas en receptores beta-adreno-receptores atipicos | |
| AR044400A1 (es) | Procesos para la preparacion de derivados de pirimidina | |
| AR072906A1 (es) | Nucleosidos modificados utiles como antivirales | |
| AR038419A1 (es) | Derivados de piridina y quinolina | |
| AR041997A1 (es) | Derivados de oxaxol sustituidos, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de la diabetes | |
| UY26143A1 (es) | Derivados heterocíclicos útiles como agentes anticancerosos | |
| AR036114A1 (es) | Tetrahidroimidazol[1,2-a]pirazinas y tetrahidrotriazol[4,3-a]pirazinas como inhibidores de la dipeptidil peptidasa utiles para el tratamiento o la prevencion de la diabetes | |
| AR031597A1 (es) | Compuestos piperidinos,un proceso para su preparacion, composiciones farmaceuticas,y el uso de dichos compuestos para la fabricacion de un medicamento para uso como inhibidores ccr-3 | |
| AR020165A1 (es) | Derivados de pirimidinas sustituidas, su procedimiento de preparacion, composiciones farmaceuticas que las contienen y el uso de los mismos para la preparacion de medicamentos | |
| AR041297A1 (es) | Derivados de 4-pirrolidino- fenil- bencil eter | |
| AR064414A1 (es) | Derivados de 1-azoniabiciclo[2, 2, 2]octano y 1-azabiciclo[2, 2, 2]oct-3-ilo, un proceso para su preparacion, una composicion farmaceutica que los comprende, procedimiento de obtencion de la misma, su uso en la elaboracion de un medicamento para el tratamiento de epoc y un producto farmaceutico que | |
| ECSP067053A (es) | 1-aza-biciclo[3.3.1]nonanos | |
| GEP20125548B (en) | New dihidroindolone compounds, a process for its preparation and pharmaceutical compositions containing them | |
| UY27803A1 (es) | Derivados de benzoxazina y usos de los mismos. | |
| AR041883A1 (es) | Compuestos de piridopirimidinona, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
| TW200519113A (en) | Novel 1, 2, 3, 6, 7, 8-substituted indolizine derivatives, inhibitors of FGFs, method for preparing them and pharmaceutical compositions containing them | |
| AR057063A1 (es) | Moduladores de tienopirimidina y tienopiridina quinasa y composicion farmaceutica | |
| ES2291722T3 (es) | Aminoalcoxiindoles como ligandos 5-ht6-receptores para el tratamiento de transtornos del snc. | |
| AR041786A1 (es) | Derivados de azetidina como antagonistas del receptor ccr-3, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la elaboracion de un medicamento |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Application granted | ||
| FD | Application lapsed |